Cover Image
市場調查報告書

GlycaNova Norway AS的產品平台分析

GlycaNova Norway AS - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 319976
出版日期 內容資訊 英文 20 Pages
訂單完成後即時交付
價格
Back to Top
GlycaNova Norway AS的產品平台分析 GlycaNova Norway AS - Product Pipeline Review - 2015
出版日期: 2015年09月30日 內容資訊: 英文 20 Pages
簡介

GlycaNova Norway AS是總公司在挪威的製藥企業,利用獨有的培養技術和分離技術,開發、製造、商品化擔子菌來源的API及醫學保健食品產品。對象疾病跨癌症、肝臟疾病、糖尿病、過敏、AIDS、皮膚疾病、高血壓、高膽固醇、慢性支氣管炎、靜脈炎、血栓症等多方面。

本報告提供GlycaNova Norway AS的治療藥開發平台的現狀及各開發階段比較分析、各藥物標靶、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

GlycaNova Norway AS的基本資料

  • GlycaNova Norway AS概要
  • 主要資訊
  • 企業資料

GlycaNova Norway AS:R&D概要

  • 主要的治療範圍

GlycaNova Norway AS:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

GlycaNova Norway AS:開發中產品概況

  • 在臨床階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

GlycaNova Norway AS:藥物簡介

  • MM-10001
  • MM-10300
  • MM-1501

GlycaNova Norway AS:開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

GlycaNova Norway AS:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07626CDB

Summary

Global Markets Direct's, 'GlycaNova Norway AS - Product Pipeline Review - 2015', provides an overview of the GlycaNova Norway AS's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of GlycaNova Norway AS's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of GlycaNova Norway AS including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of GlycaNova Norway AS's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the GlycaNova Norway AS's pipeline products

Reasons to buy

  • Evaluate GlycaNova Norway AS's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of GlycaNova Norway AS in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the GlycaNova Norway AS's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of GlycaNova Norway AS and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of GlycaNova Norway AS
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of GlycaNova Norway AS and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • GlycaNova Norway AS Snapshot
    • GlycaNova Norway AS Overview
    • Key Information
    • Key Facts
  • GlycaNova Norway AS - Research and Development Overview
    • Key Therapeutic Areas
  • GlycaNova Norway AS - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • GlycaNova Norway AS - Pipeline Products Glance
    • GlycaNova Norway AS - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • GlycaNova Norway AS - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • GlycaNova Norway AS - Drug Profiles
    • MM-10001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MM-10300
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MM-1501
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • GlycaNova Norway AS - Pipeline Analysis
  • GlycaNova Norway AS - Pipeline Products by Target
  • GlycaNova Norway AS - Pipeline Products by Route of Administration
  • GlycaNova Norway AS - Pipeline Products by Molecule Type
  • GlycaNova Norway AS - Pipeline Products by Mechanism of Action
  • GlycaNova Norway AS - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • GlycaNova Norway AS, Key Information
  • GlycaNova Norway AS, Key Facts
  • GlycaNova Norway AS - Pipeline by Indication, 2015
  • GlycaNova Norway AS - Pipeline by Stage of Development, 2015
  • GlycaNova Norway AS - Monotherapy Products in Pipeline, 2015
  • GlycaNova Norway AS - Phase I, 2015
  • GlycaNova Norway AS - Preclinical, 2015
  • GlycaNova Norway AS - Pipeline by Target, 2015
  • GlycaNova Norway AS - Pipeline by Route of Administration, 2015
  • GlycaNova Norway AS - Pipeline by Molecule Type, 2015
  • GlycaNova Norway AS - Pipeline Products by Mechanism of Action, 2015

List of Figures

  • GlycaNova Norway AS - Pipeline by Top 10 Indication, 2015
  • GlycaNova Norway AS - Pipeline by Stage of Development, 2015
  • GlycaNova Norway AS - Monotherapy Products in Pipeline, 2015
  • GlycaNova Norway AS - Pipeline by Top 10 Route of Administration, 2015
  • GlycaNova Norway AS - Pipeline by Top 10 Molecule Type, 2015
Back to Top